🔗 Share this article

While America proceeds with unprecedented adjustments to its immunization guidelines, an unexpected name appears somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccines in the global health crisis and has zeroed in on alleged deaths after COVID-19 vaccination in her recent position at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Agency leaders had intended to reveal sweeping changes to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would put the US out of step with much of the international standard with no evidence for benefit. The announcement has been postponed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to present at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

Consolidating Power at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has often pushed for ending specific pediatric vaccine recommendations in the US in order to be more similar to Denmark, a country with comprehensive healthcare and a population about the population of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – traditionally the purview of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Questions Over Expertise

Høeg has no obvious track record in pharmaceutical research, oversight or administrative roles, which has been standard for previous directors of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for overseeing the CDER, said Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Former directors of the center would “understand laws and regulations and the research of drug development”, noted a former acting FDA commissioner. “Clearly, she lacks the type of experience that prior appointees who ran the center have had.”

CDER has an vast range of responsibilities at the agency, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic program approves a multitude of generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and all of those need to be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major management element to the position, which manages in excess of 5,000 staff members. “It is a enormous leadership role, if you execute it properly,” Woodcock added.

Response and Disputed Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among regulatory chiefs on immunizations, a representative stated that the “inquiries are based on incorrect presumptions”.

“Her resume is consistent with the duties of her role,” the spokesperson said, citing the time Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial one-day medication authorization process that apparently worried her predecessors. “How are these medications being picked for this expedited pathway? Who makes the choices?” Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of all drugs, aside from immunizations.”

Public Past Work on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, past, some experts said. She published a study using non-validated volunteer-provided data to estimate the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the incoming government included altering guidelines for novel immunizations and ending “optional” vaccines, she stated following the vote on a podcast. At the FDA, Høeg has reportedly floated the idea of preventing teenage boys from obtaining Covid vaccines.

“She is an all-around true believer who commences with her conclusions and reverse-engineers to retrofit the science in a extremely deceptive, dishonest fashion,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Høeg became part of fellow dissenters, {like|